AVBP
AVBP clinical trials: ArriVent BioPharma, Inc.
Every trial on ClinicalTrials.gov where ArriVent BioPharma, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 6
- Trials linked
- 5
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
AVBP on the catalyst calendar · AVBP registry changes
- Primary completion Jun 3, 2025ActualPhase 1NCT05364073Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon...ArriVent BioPharma, Inc. · Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingAVBPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2029Sponsor estimatePhase 3NCT07185997Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in...ArriVent BioPharma, Inc. · Non-Small-Cell Lung CancerRecruitingAVBPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 6, 2026ActualPhase 3NCT05607550Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung...ArriVent BioPharma, Inc. · Metastatic Non-Small Cell Lung CancerActive, not recruitingAVBPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2027Sponsor estimatePhase 1NCT07755436Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or...ArriVent BioPharma, Inc. · Ovarian CancerRecruitingAVBPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2028Sponsor estimatePhase 1NCT07066657A Study of MRG007 (ARR-217) in Patients With Advanced Solid TumorsArriVent BioPharma, Inc. · Locally Advanced or Metastatic Solid TumorsRecruitingAVBPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 31, 2028Sponsor estimatePhase 3NCT07010419A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB...Allist Pharmaceuticals, Inc. · NSCLCRecruitingAVBPCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 6 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner